Annual EBITDA
-$23.01 M
+$6.16 M+21.11%
December 31, 2023
Summary
- As of February 7, 2025, CAPR annual EBITDA is -$23.01 million, with the most recent change of +$6.16 million (+21.11%) on December 31, 2023.
- During the last 3 years, CAPR annual EBITDA has fallen by -$9.46 million (-69.86%).
- CAPR annual EBITDA is now -873.57% below its all-time high of $2.97 million, reached on December 31, 2017.
Performance
CAPR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$12.65 M
-$1.41 M-12.59%
September 30, 2024
Summary
- As of February 7, 2025, CAPR quarterly EBITDA is -$12.65 million, with the most recent change of -$1.41 million (-12.59%) on September 30, 2024.
- Over the past year, CAPR quarterly EBITDA has dropped by -$1.41 million (-12.59%).
- CAPR quarterly EBITDA is now -201.84% below its all-time high of $12.42 million, reached on December 31, 2017.
Performance
CAPR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$34.79 M
-$6.06 M-21.09%
September 30, 2024
Summary
- As of February 7, 2025, CAPR TTM EBITDA is -$34.79 million, with the most recent change of -$6.06 million (-21.09%) on September 30, 2024.
- Over the past year, CAPR TTM EBITDA has dropped by -$6.06 million (-21.09%).
- CAPR TTM EBITDA is now -1269.65% below its all-time high of $2.97 million, reached on December 31, 2017.
Performance
CAPR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CAPR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +21.1% | -12.6% | -21.1% |
| 3 y3 years | -69.9% | -60.6% | -19.3% |
| 5 y5 years | -51.7% | -60.6% | -19.3% |
CAPR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -11.2% | +21.1% | -1199.0% | at low | -68.1% | at low |
| 5 y | 5-year | -204.3% | +21.1% | -1199.0% | at low | -388.5% | at low |
| alltime | all time | -873.6% | +21.1% | -201.8% | at low | -1269.7% | at low |
Capricor Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$12.65 M(+12.6%) | -$34.79 M(+21.1%) |
| Jun 2024 | - | -$11.23 M(+13.1%) | -$28.73 M(+15.0%) |
| Mar 2024 | - | -$9.93 M(+920.3%) | -$24.99 M(+8.6%) |
| Dec 2023 | -$23.01 M(-21.1%) | -$973.70 K(-85.2%) | -$23.01 M(-23.1%) |
| Sep 2023 | - | -$6.59 M(-12.1%) | -$29.91 M(+0.8%) |
| Jun 2023 | - | -$7.49 M(-5.8%) | -$29.66 M(+1.0%) |
| Mar 2023 | - | -$7.95 M(+1.0%) | -$29.38 M(+0.7%) |
| Dec 2022 | -$29.16 M(+40.9%) | -$7.87 M(+24.2%) | -$29.16 M(+5.7%) |
| Sep 2022 | - | -$6.34 M(-12.1%) | -$27.59 M(+8.2%) |
| Jun 2022 | - | -$7.21 M(-6.8%) | -$25.50 M(+9.3%) |
| Mar 2022 | - | -$7.74 M(+22.8%) | -$23.32 M(+12.7%) |
| Dec 2021 | -$20.69 M(+52.8%) | -$6.30 M(+48.3%) | -$20.69 M(+11.7%) |
| Sep 2021 | - | -$4.25 M(-15.5%) | -$18.53 M(+2.0%) |
| Jun 2021 | - | -$5.03 M(-1.6%) | -$18.16 M(+9.5%) |
| Mar 2021 | - | -$5.11 M(+23.5%) | -$16.58 M(+22.4%) |
| Dec 2020 | -$13.55 M(+79.1%) | -$4.14 M(+6.7%) | -$13.55 M(+24.9%) |
| Sep 2020 | - | -$3.88 M(+12.2%) | -$10.85 M(+26.8%) |
| Jun 2020 | - | -$3.46 M(+66.6%) | -$8.56 M(+20.1%) |
| Mar 2020 | - | -$2.07 M(+44.0%) | -$7.12 M(-5.8%) |
| Dec 2019 | -$7.56 M(-50.2%) | -$1.44 M(-9.1%) | -$7.56 M(-19.4%) |
| Sep 2019 | - | -$1.58 M(-21.6%) | -$9.38 M(-21.3%) |
| Jun 2019 | - | -$2.02 M(-19.5%) | -$11.93 M(-15.0%) |
| Mar 2019 | - | -$2.51 M(-23.0%) | -$14.03 M(-7.5%) |
| Dec 2018 | -$15.17 M(-610.0%) | -$3.26 M(-21.0%) | -$15.17 M(-3054.7%) |
| Sep 2018 | - | -$4.13 M(+0.2%) | $513.40 K(-75.0%) |
| Jun 2018 | - | -$4.12 M(+12.9%) | $2.05 M(-27.9%) |
| Mar 2018 | - | -$3.65 M(-129.4%) | $2.84 M(-4.4%) |
| Dec 2017 | $2.97 M(-116.2%) | $12.42 M(-578.8%) | $2.97 M(-121.5%) |
| Sep 2017 | - | -$2.59 M(-22.1%) | -$13.83 M(-15.9%) |
| Jun 2017 | - | -$3.33 M(-5.5%) | -$16.44 M(-7.1%) |
| Mar 2017 | - | -$3.52 M(-19.6%) | -$17.69 M(-3.5%) |
| Dec 2016 | -$18.34 M(+46.7%) | -$4.38 M(-15.9%) | -$18.34 M(+6.6%) |
| Sep 2016 | - | -$5.21 M(+13.7%) | -$17.21 M(+16.1%) |
| Jun 2016 | - | -$4.58 M(+9.8%) | -$14.82 M(+11.6%) |
| Mar 2016 | - | -$4.17 M(+28.2%) | -$13.28 M(+6.2%) |
| Dec 2015 | -$12.50 M(+109.2%) | -$3.25 M(+15.2%) | -$12.50 M(+12.6%) |
| Sep 2015 | - | -$2.82 M(-7.0%) | -$11.10 M(+13.8%) |
| Jun 2015 | - | -$3.04 M(-10.5%) | -$9.75 M(+19.1%) |
| Mar 2015 | - | -$3.39 M(+82.8%) | -$8.19 M(+37.0%) |
| Dec 2014 | -$5.97 M(-32.2%) | -$1.85 M(+26.0%) | -$5.97 M(-28.8%) |
| Sep 2014 | - | -$1.47 M(+0.2%) | -$8.39 M(-0.5%) |
| Jun 2014 | - | -$1.47 M(+24.7%) | -$8.44 M(-1.6%) |
| Mar 2014 | - | -$1.18 M(-72.4%) | -$8.58 M(-2.6%) |
| Dec 2013 | -$8.81 M(+329.4%) | -$4.27 M(+182.0%) | -$8.81 M(+79.8%) |
| Sep 2013 | - | -$1.52 M(-5.9%) | -$4.90 M(+24.1%) |
| Jun 2013 | - | -$1.61 M(+14.5%) | -$3.95 M(+106.3%) |
| Mar 2013 | - | -$1.41 M(+285.9%) | -$1.91 M(+49.9%) |
| Dec 2012 | -$2.05 M | -$364.70 K(-35.4%) | -$1.28 M(-50.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | -$564.80 K(-233.5%) | -$2.57 M(-18.3%) |
| Jun 2012 | - | $423.00 K(-154.9%) | -$3.15 M(-29.2%) |
| Mar 2012 | - | -$770.10 K(-53.7%) | -$4.45 M(-8.7%) |
| Dec 2011 | -$4.88 M(-22.3%) | -$1.66 M(+45.6%) | -$4.88 M(+14.6%) |
| Sep 2011 | - | -$1.14 M(+30.0%) | -$4.26 M(-13.6%) |
| Jun 2011 | - | -$878.40 K(-26.5%) | -$4.92 M(-11.2%) |
| Mar 2011 | - | -$1.20 M(+14.9%) | -$5.54 M(-11.7%) |
| Dec 2010 | -$6.28 M(-18.7%) | -$1.04 M(-42.5%) | -$6.28 M(-7.5%) |
| Sep 2010 | - | -$1.81 M(+20.8%) | -$6.79 M(-2.6%) |
| Jun 2010 | - | -$1.50 M(-22.5%) | -$6.97 M(-12.3%) |
| Mar 2010 | - | -$1.93 M(+24.9%) | -$7.95 M(+2.9%) |
| Dec 2009 | -$7.72 M(-41.9%) | -$1.55 M(-22.3%) | -$7.72 M(-15.6%) |
| Sep 2009 | - | -$1.99 M(-19.5%) | -$9.15 M(-12.9%) |
| Jun 2009 | - | -$2.47 M(+44.6%) | -$10.50 M(-11.4%) |
| Mar 2009 | - | -$1.71 M(-42.4%) | -$11.85 M(-10.8%) |
| Dec 2008 | -$13.29 M(+40.3%) | -$2.97 M(-11.2%) | -$13.29 M(+2.0%) |
| Sep 2008 | - | -$3.35 M(-12.4%) | -$13.02 M(-9.0%) |
| Jun 2008 | - | -$3.82 M(+21.2%) | -$14.31 M(+20.1%) |
| Mar 2008 | - | -$3.15 M(+16.6%) | -$11.91 M(+25.8%) |
| Dec 2007 | -$9.47 M(+279.2%) | -$2.70 M(-41.6%) | -$9.47 M(+29.1%) |
| Sep 2007 | - | -$4.63 M(+225.2%) | -$7.34 M(+110.3%) |
| Jun 2007 | - | -$1.42 M(+100.1%) | -$3.49 M(+69.8%) |
| Mar 2007 | - | -$711.90 K(+25.7%) | -$2.05 M(+52.2%) |
| Dec 2006 | -$2.50 M(>+9900.0%) | -$566.20 K(-27.9%) | -$1.35 M(+70.7%) |
| Sep 2006 | - | -$785.10 K(-8823.3%) | -$790.40 K(+8985.1%) |
| Jun 2006 | - | $9000.00(-225.0%) | -$8700.00(-57.8%) |
| Mar 2006 | - | -$7200.00(+1.4%) | -$20.60 K(+9.6%) |
| Dec 2005 | -$18.90 K(-0.5%) | -$7100.00(+108.8%) | -$18.80 K(-14.2%) |
| Sep 2005 | - | -$3400.00(+17.2%) | -$21.90 K(-0.5%) |
| Jun 2005 | - | -$2900.00(-46.3%) | -$22.00 K(0.0%) |
| Mar 2005 | - | -$5400.00(-47.1%) | -$22.00 K(+15.2%) |
| Dec 2004 | -$19.00 K(+17.3%) | -$10.20 K(+191.4%) | -$19.10 K(+33.6%) |
| Sep 2004 | - | -$3500.00(+20.7%) | -$14.30 K(+31.2%) |
| Jun 2004 | - | -$2900.00(+16.0%) | -$10.90 K(-27.3%) |
| Mar 2004 | - | -$2500.00(-53.7%) | -$15.00 K(-7.4%) |
| Dec 2003 | -$16.20 K(-9.0%) | -$5400.00(+5300.0%) | -$16.20 K(+11.0%) |
| Sep 2003 | - | -$100.00(-98.6%) | -$14.60 K(-36.8%) |
| Jun 2003 | - | -$7000.00(+89.2%) | -$23.10 K(-16.6%) |
| Mar 2003 | - | -$3700.00(-2.6%) | -$27.70 K(+55.6%) |
| Dec 2002 | -$17.80 K(-19.8%) | -$3800.00(-55.8%) | -$17.80 K(+6.0%) |
| Sep 2002 | - | -$8600.00(-25.9%) | -$16.80 K(+30.2%) |
| Jun 2002 | - | -$11.60 K(-287.1%) | -$12.90 K(+87.0%) |
| Mar 2002 | - | $6200.00(-321.4%) | -$6900.00(-68.9%) |
| Dec 2001 | -$22.20 K(-38.8%) | -$2800.00(-40.4%) | -$22.20 K(+14.4%) |
| Sep 2001 | - | -$4700.00(-16.1%) | -$19.40 K(+32.0%) |
| Jun 2001 | - | -$5600.00(-38.5%) | -$14.70 K(+61.5%) |
| Mar 2001 | - | -$9100.00 | -$9100.00 |
| Dec 2000 | -$36.30 K(<-9900.0%) | - | - |
| Dec 1999 | $0.00 | - | - |
FAQ
- What is Capricor Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Capricor Therapeutics?
- What is Capricor Therapeutics annual EBITDA year-on-year change?
- What is Capricor Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Capricor Therapeutics?
- What is Capricor Therapeutics quarterly EBITDA year-on-year change?
- What is Capricor Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Capricor Therapeutics?
- What is Capricor Therapeutics TTM EBITDA year-on-year change?
What is Capricor Therapeutics annual EBITDA?
The current annual EBITDA of CAPR is -$23.01 M
What is the all time high annual EBITDA for Capricor Therapeutics?
Capricor Therapeutics all-time high annual EBITDA is $2.97 M
What is Capricor Therapeutics annual EBITDA year-on-year change?
Over the past year, CAPR annual EBITDA has changed by +$6.16 M (+21.11%)
What is Capricor Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CAPR is -$12.65 M
What is the all time high quarterly EBITDA for Capricor Therapeutics?
Capricor Therapeutics all-time high quarterly EBITDA is $12.42 M
What is Capricor Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CAPR quarterly EBITDA has changed by -$1.41 M (-12.59%)
What is Capricor Therapeutics TTM EBITDA?
The current TTM EBITDA of CAPR is -$34.79 M
What is the all time high TTM EBITDA for Capricor Therapeutics?
Capricor Therapeutics all-time high TTM EBITDA is $2.97 M
What is Capricor Therapeutics TTM EBITDA year-on-year change?
Over the past year, CAPR TTM EBITDA has changed by -$6.06 M (-21.09%)